[go: up one dir, main page]

WO2005075679A3 - Antigenic hiv-1 peptides - Google Patents

Antigenic hiv-1 peptides Download PDF

Info

Publication number
WO2005075679A3
WO2005075679A3 PCT/IT2005/000058 IT2005000058W WO2005075679A3 WO 2005075679 A3 WO2005075679 A3 WO 2005075679A3 IT 2005000058 W IT2005000058 W IT 2005000058W WO 2005075679 A3 WO2005075679 A3 WO 2005075679A3
Authority
WO
WIPO (PCT)
Prior art keywords
peptides
antigenic hiv
hiv
antigenic
populations
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IT2005/000058
Other languages
French (fr)
Other versions
WO2005075679A2 (en
Inventor
Massimo Amicosante
Giulia Cappelli
Vittorio Colizzi
Arrigo Roberta D
Francesco Dieli
Carlo Federico Perno
Alessandra Sacchi
Alfredo Salerno
Luc Montagner
Henri Chenal
Thomas Toni
Jacques Simpore
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Consiglio Nazionale delle Richerche CNR
Universita degli Studi di Roma Tor Vergata
Universita degli Studi di Roma La Sapienza
Universita degli Studi di Palermo
Original Assignee
Consiglio Nazionale delle Richerche CNR
Universita degli Studi di Roma Tor Vergata
Universita degli Studi di Roma La Sapienza
Universita degli Studi di Palermo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Consiglio Nazionale delle Richerche CNR, Universita degli Studi di Roma Tor Vergata, Universita degli Studi di Roma La Sapienza, Universita degli Studi di Palermo filed Critical Consiglio Nazionale delle Richerche CNR
Publication of WO2005075679A2 publication Critical patent/WO2005075679A2/en
Publication of WO2005075679A3 publication Critical patent/WO2005075679A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention refers to a method of antigenic peptide identification and to the relative use for the preparation of a specific vaccine against HIV-1 for the populations of sub-Saharan Africa.
PCT/IT2005/000058 2004-02-09 2005-02-08 Antigenic hiv-1 peptides Ceased WO2005075679A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITRM20040066 ITRM20040066A1 (en) 2004-02-09 2004-02-09 METHOD OF IDENTIFICATION OF ANTIGENIC PEPTIDES AND RELATED USE FOR THE PREPARATION OF AN ANTI HIV-1 VACCINE.
ITRM2004A000066 2004-02-09

Publications (2)

Publication Number Publication Date
WO2005075679A2 WO2005075679A2 (en) 2005-08-18
WO2005075679A3 true WO2005075679A3 (en) 2005-12-08

Family

ID=34835614

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IT2005/000058 Ceased WO2005075679A2 (en) 2004-02-09 2005-02-08 Antigenic hiv-1 peptides

Country Status (2)

Country Link
IT (1) ITRM20040066A1 (en)
WO (1) WO2005075679A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007055260A1 (en) * 2005-11-11 2007-05-18 Japan Health Sciences Foundation Material for detection or quantification of human immunodeficiency virus-1 gene, detection or quantification method, gene fragment for therapy, and therapeutic method
CA2825273A1 (en) * 2011-01-20 2012-07-26 Oneday - Biotech And Pharma Ltd. Antioxidant, anti-inflammatory, anti-radiation, metal chelating compounds and uses thereof
WO2014016831A1 (en) 2012-07-23 2014-01-30 Oneday - Biotech And Pharma Ltd. Glutathione-elevating compositions and uses thereof
WO2014016837A1 (en) 2012-07-25 2014-01-30 Oneday - Biotech And Pharma Ltd. Compositions and methods for increasing carnitine level in muscle tissues
WO2014037712A2 (en) * 2012-09-04 2014-03-13 Genome Research Limited Hiv-1 detection

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001004361A2 (en) * 1999-07-09 2001-01-18 Gen-Probe Incorporated Detection of hiv-1 by nucleic acid amplification

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001004361A2 (en) * 1999-07-09 2001-01-18 Gen-Probe Incorporated Detection of hiv-1 by nucleic acid amplification

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
AMICOSANTE M ET AL: "Computer-based design of an HLA-haplotype and HIV-clade independent cytotoxic T-lymphocyte (CTL) assay for monitoring HIV-specific immunity", MOLECULAR MEDICINE, BLACKWELL SCIENCE, CAMBRIDGE, MA, US, vol. 8, no. 12, December 2002 (2002-12-01), pages 798 - 807, XP002285458, ISSN: 1076-1551 *
GROOT DE A S ET AL: "USE OF BIOINFORMATICS TO PREDICT MHC LIGANDS AND T-CELL EPITOPES: APPLICATION TO EPITOPE-DRIVEN VACCINE DESIGN", METHODS IN MICROBIOLOGY, XX, XX, vol. 32, 2002, pages 99 - 123, XP008050037 *
HAYNES B F: "HIV vaccines: where we are and where we are going", LANCET THE, LANCET LIMITED. LONDON, GB, vol. 348, no. 9032, 5 October 1996 (1996-10-05), pages 933 - 937, XP004837237, ISSN: 0140-6736 *
MCMICHAEL ANDREW J ET AL: "HIV vaccines 1983-2003.", NATURE MEDICINE, vol. 9, no. 7, July 2003 (2003-07-01), pages 874 - 880, XP002336478, ISSN: 1078-8956 *
ZENG GANG ET AL: "Generation of NY-ESO-1-specific CD4+ and CD8+ T cells by a single peptide with dual MHC class I and class II specificities: A new strategy for vaccine design", CANCER RESEARCH, vol. 62, no. 13, 1 July 2002 (2002-07-01), pages 3630 - 3635, XP002336479, ISSN: 0008-5472 *

Also Published As

Publication number Publication date
WO2005075679A2 (en) 2005-08-18
ITRM20040066A1 (en) 2004-05-09

Similar Documents

Publication Publication Date Title
EP2526966A3 (en) Herpes simplex virus combined subunit vaccines and methods of use thereof
WO2004080403A3 (en) Influenza virus vaccine
WO2005087261A3 (en) Identification of self and non-self antigens implicated in autoimmune diseases
CY1107146T1 (en) METHODS FOR THE PREVENTION AND TREATMENT OF ALZHEIMER'S DISEASE (AD)
UA103751C2 (en) Immunogenic peptide for immunotherapy
PT1409692E (en) Novel peptides of the respiratory syncytial virus (rsv) g protein and their use in a vaccine
TW200634051A (en) Processes for preparing a polypeptide
WO2006005707A3 (en) Method for preventing and treating alzheimer´s disease
WO2006115843A3 (en) Nipah virus vaccines
WO2006081826A3 (en) Survivin peptide vaccine
MX2009013635A (en) Influenza inhibiting compositions and methods.
WO2007100580A3 (en) Antibodies recognizing a highly expressed putative antigen of ca-mrsa and methods of use
WO2008098749A3 (en) Peptides derived from the major allergen of ragweed (ambrosia artemisiifolia) and uses thereof
MX355054B (en) Hig2 and urlc10 epitope peptide and vaccines containing the same.
TW200621287A (en) Vaccines
WO2006110831A3 (en) Method of inducing neutralizing antibodies to human immunodeficiency virus
WO2005075679A3 (en) Antigenic hiv-1 peptides
WO2002058725A3 (en) Non-glycosylated peptides derived from the rsv g protein and use thereof in a vaccine
WO2010057242A3 (en) Vaccine
WO2002076498A3 (en) Bacteriophage-mediated immunisation
MX2011004176A (en) Rab6kifl/kif20a epitope peptide and vaccines containing the same.
WO2006007555A3 (en) Rotavirus antigens
IL307601A (en) Magec2 immunogenic peptides, binding proteins recognizing magec2 immunogenic peptides, and uses thereof
WO2006062917A3 (en) Alpha thymosin peptides as cancer vaccine adjuvants
WO2010041237A3 (en) Cyclic v3 peptides for anti hiv-1 vaccine

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Country of ref document: DE

122 Ep: pct application non-entry in european phase